WallStreetZenWallStreetZen

NASDAQ: KRMD
Koru Medical Systems Inc Stock Forecast, Predictions & Price Target

Analyst price target for KRMD

Based on 1 analyst offering 12 month price targets for Koru Medical Systems Inc.
Min Forecast
$3.00+20%
Avg Forecast
$3.00+20%
Max Forecast
$3.00+20%

Should I buy or sell KRMD stock?

Based on 1 analyst offering ratings for Koru Medical Systems Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their KRMD stock forecasts and price targets.

KRMD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-08

1 of 1

Forecast return on equity

Is KRMD forecast to generate an efficient return?
Company
-4.9%
Industry
17.4%
Market
52.58%
KRMD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is KRMD forecast to generate an efficient return on assets?
Company
-3.36%
Industry
12%
KRMD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

KRMD earnings per share forecast

What is KRMD's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.13
Avg 2 year Forecast
-$0.09
Avg 3 year Forecast
-$0.02

KRMD revenue forecast

What is KRMD's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$32.3M+4.75%
Avg 2 year Forecast
$37.6M+22.16%
Avg 3 year Forecast
$45.1M+46.19%
KRMD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

KRMD revenue growth forecast

How is KRMD forecast to perform vs Medical Instruments & Supplies companies and vs the US market?
Company
11.38%
Industry
7.18%
Market
8.31%
KRMD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
KRMD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

KRMD vs Medical Stocks

TickerPricePrice TargetUp/downsideConsensus
KRMD$2.50$3.00+20.00%Strong Buy
HBIO$2.88N/AN/A
INFU$6.51N/AN/A
PDEX$26.69$30.00+12.40%Buy
ZTEK$0.87N/AN/A

Koru Medical Systems Stock Forecast FAQ

Is Koru Medical Systems Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: KRMD) stock is to Strong Buy KRMD stock.

Out of 1 analyst, 1 (100%) are recommending KRMD as a Strong Buy, 0 (0%) are recommending KRMD as a Buy, 0 (0%) are recommending KRMD as a Hold, 0 (0%) are recommending KRMD as a Sell, and 0 (0%) are recommending KRMD as a Strong Sell.

If you're new to stock investing, here's how to buy Koru Medical Systems stock.

What is KRMD's earnings growth forecast for 2024-2026?

(NASDAQ: KRMD) Koru Medical Systems's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Instruments & Supplies industry's average forecast earnings growth rate of 20.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.15%.

Koru Medical Systems's earnings in 2024 is -$11,758,964.On average, 2 Wall Street analysts forecast KRMD's earnings for 2024 to be -$5,961,193, with the lowest KRMD earnings forecast at -$5,961,193, and the highest KRMD earnings forecast at -$5,961,193. On average, 2 Wall Street analysts forecast KRMD's earnings for 2025 to be -$3,897,703, with the lowest KRMD earnings forecast at -$4,585,533, and the highest KRMD earnings forecast at -$3,209,873.

In 2026, KRMD is forecast to generate -$917,107 in earnings, with the lowest earnings forecast at -$917,107 and the highest earnings forecast at -$917,107.

What is KRMD's revenue growth forecast for 2024-2026?

(NASDAQ: KRMD) Koru Medical Systems's forecast annual revenue growth rate of 11.38% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.18%, and it is also forecast to beat the US market's average forecast revenue growth rate of 8.31%.

Koru Medical Systems's revenue in 2024 is $30,817,017.On average, 2 Wall Street analysts forecast KRMD's revenue for 2024 to be $1,480,209,988, with the lowest KRMD revenue forecast at $1,476,541,562, and the highest KRMD revenue forecast at $1,483,878,414. On average, 2 Wall Street analysts forecast KRMD's revenue for 2025 to be $1,726,223,823, with the lowest KRMD revenue forecast at $1,714,989,267, and the highest KRMD revenue forecast at $1,737,458,378.

In 2026, KRMD is forecast to generate $2,065,782,526 in revenue, with the lowest revenue forecast at $2,065,782,526 and the highest revenue forecast at $2,065,782,526.

What is KRMD's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: KRMD) forecast ROA is -3.36%, which is lower than the forecast US Medical Instruments & Supplies industry average of 12%.

What is KRMD's Price Target?

According to 1 Wall Street analyst that have issued a 1 year KRMD price target, the average KRMD price target is $3.00, with the highest KRMD stock price forecast at $3.00 and the lowest KRMD stock price forecast at $3.00.

The Wall Street analyst predicted that Koru Medical Systems's share price could reach $3.00 by Aug 8, 2025. The average Koru Medical Systems stock price prediction forecasts a potential upside of 20% from the current KRMD share price of $2.50.

What is KRMD's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: KRMD) Koru Medical Systems's current Earnings Per Share (EPS) is -$0.25. On average, analysts forecast that KRMD's EPS will be -$0.13 for 2024, with the lowest EPS forecast at -$0.13, and the highest EPS forecast at -$0.13. On average, analysts forecast that KRMD's EPS will be -$0.09 for 2025, with the lowest EPS forecast at -$0.10, and the highest EPS forecast at -$0.07. In 2026, KRMD's EPS is forecast to hit -$0.02 (min: -$0.02, max: -$0.02).

What is KRMD's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: KRMD) forecast ROE is -4.9%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.